Effects of CX516 on Functioning in Fragile X Syndrome and Autism
|ClinicalTrials.gov Identifier: NCT00054730|
Recruitment Status : Completed
First Posted : February 11, 2003
Last Update Posted : June 24, 2005
This study will investigate whether CX516 can improve attention, memory, language, or behavior in adults with Fragile X Syndrome and/or Autism.
CX516 is an AMPAKINE® compound. AMPAKINE compounds enhance synaptic strength. There is evidence to suggest that the synapses in the brain of an individual with fragile X syndrome are immature and abnormal. It is possible CX516 may partially correct this synaptic transmission defect and lead to improvement in cognitive and behavioral functioning.
There is also reason to believe that these changes caused by CX516 could be helpful in managing cognitive and behavioral symptoms in patients with autistic disorder.
Involvement for each participant will last 28 days. Participants will be given study medication, a physical exam, and a variety of cognitive assessment tests to study potential drug effectiveness at improving disease symptoms.
|Condition or disease||Intervention/treatment||Phase|
|Fragile X Syndrome Autism||Drug: CX516 (Ampalex®)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism|
|Study Start Date :||June 2002|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054730
|United States, California|
|UC Davis-MIND Institute|
|Sacramento, California, United States, 95817|
|United States, Illinois|
|RUSH-Presbyterian-St. Luke's Medical Center|
|Chicago, Illinois, United States, 60612|